Bemfola

Maa: Euroopan unioni

Kieli: englanti

Lähde: EMA (European Medicines Agency)

Osta se nyt

Pakkausseloste Pakkausseloste (PIL)
17-01-2024
Valmisteyhteenveto Valmisteyhteenveto (SPC)
17-01-2024

Aktiivinen ainesosa:

follitropin alfa

Saatavilla:

Gedeon Richter Plc.

ATC-koodi:

G03GA05

INN (Kansainvälinen yleisnimi):

follitropin alfa

Terapeuttinen ryhmä:

Sex hormones and modulators of the genital system,

Terapeuttinen alue:

Anovulation

Käyttöaiheet:

In adult women:anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate;stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian transfer (GIFT) and zygote intra-fallopian transfer (ZIFT);follitropin alfa in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level < 1.2 IU/l.In adult men:follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human Chorionic Gonadotrophin (hCG) therapy.

Tuoteyhteenveto:

Revision: 10

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

2014-03-26

Pakkausseloste

                                38
B. PACKAGE LEAFLET
39
PACKAGE LEAFLET: INFORMATION FOR THE USER
BEMFOLA 75 IU/0.125 ML SOLUTION
FOR INJECTION IN PRE-FILLED PEN
BEMFOLA 150 IU/0.25 ML SOLUTION
FOR INJECTION IN PRE-FILLED PEN
BEMFOLA 225 IU/0.375 ML SOLUTION
FOR INJECTION IN PRE-FILLED PEN
BEMFOLA 300 IU/0.50 ML SOLUTION
FOR INJECTION IN PRE-FILLED PEN
BEMFOLA 450 IU/0.75 ML SOLUTION
FOR INJECTION IN PRE-FILLED PEN
follitropin alfa
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE
BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects,talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Bemfola is and what it is used for
2.
What you need to know before you use Bemfola
3.
How to use Bemfola
4.
Possible side effects
5.
How to store Bemfola
6.
Contents of the pack and other information
1.
WHAT BEMFOLA IS AND WHAT IT IS USED FOR
WHAT BEMFOLA IS
This medicine contains the active substance follitropin alfa, which is
almost identical to a natural
hormone produced by your body called “follicle-stimulating
hormone” (FSH). FSH is a gonadotropin,
a type of hormone that plays an important role in human fertility and
reproduction. In women, FSH is
needed for the growth and development of the sacs (follicles) in the
ovaries that contain the egg cells.
In men, FSH is needed for the production of sperm.
WHAT BEMFOLA IS USED FOR
IN ADULT WOMEN
, Bemfola is used:
•
to help release an egg from the ovary (ovulation) in women that cannot
ovulate and that did not
respond to treatment with a medicine called “clomiphene citrate”.
•
together with another medicine called “lutropin alfa”
(“luteinising hormone” or LH) to help
release an egg fr
                                
                                Lue koko asiakirja
                                
                            

Valmisteyhteenveto

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Bemfola 75 IU/0.125 mL solution for injection in pre-filled pen
Bemfola 150 IU/0.25 mL solution for injection in pre-filled pen
Bemfola 225 IU/0.375 mL solution for injection in pre-filled pen
Bemfola 300 IU/0.50 mL solution for injection in pre-filled pen
Bemfola 450 IU/0.75 mL solution for injection in pre-filled pen
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each mL of the solution contains 600 IU (equivalent to 44 micrograms)
of follitropin alfa*.
Bemfola 75 IU/0.125 mL solution for injection in pre-filled pen:
Each pre-filled pen delivers 75 IU (equivalent to 5.5 micrograms) in
0.125 mL.
Bemfola 150 IU/0.25 mL solution for injection in pre-filled pen:
Each pre-filled pen delivers 150 IU (equivalent to 11 micrograms) in
0.25 mL.
Bemfola 225 IU/0.375 mL solution for injection in pre-filled pen:
Each pre-filled pen delivers 225 IU (equivalent to 16.5 micrograms) in
0.375 mL.
Bemfola 300 IU/0.50 mL solution for injection in pre-filled pen:
Each pre-filled pen delivers 300 IU (equivalent to 22 micrograms) in
0.5 mL.
Bemfola 450 IU/0.75 mL solution for injection in pre-filled pen:
Each pre-filled pen delivers 450 IU (equivalent to 33 micrograms) in
0.75 mL.
* recombinant human follicle stimulating hormone (r-hFSH) produced in
Chinese Hamster Ovary
(CHO) cells by recombinant DNA technology.
_ _
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection (injection).
Clear colourless solution.
The pH of the solution is 6.7 to 7.3.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
In adult women
•
Anovulation (including polycystic ovarian syndrome) in women who have
been unresponsive to
treatment with clomiphene citrate.
•
Stimulation of multifollicular development in women undergoing
superovulation for assisted
reproductive technologies (ART) such as
_in vitro_
fertilisation (IVF), gamete intra-fallopian
transfer and zygote intra-fallopian transfer.
•
Follitropin alfa in association with a lut
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Pakkausseloste Pakkausseloste bulgaria 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto bulgaria 17-01-2024
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta bulgaria 16-05-2014
Pakkausseloste Pakkausseloste espanja 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto espanja 17-01-2024
Pakkausseloste Pakkausseloste tšekki 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto tšekki 17-01-2024
Pakkausseloste Pakkausseloste tanska 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto tanska 17-01-2024
Pakkausseloste Pakkausseloste saksa 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto saksa 17-01-2024
Pakkausseloste Pakkausseloste viro 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto viro 17-01-2024
Pakkausseloste Pakkausseloste kreikka 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto kreikka 17-01-2024
Pakkausseloste Pakkausseloste ranska 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto ranska 17-01-2024
Pakkausseloste Pakkausseloste italia 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto italia 17-01-2024
Pakkausseloste Pakkausseloste latvia 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto latvia 17-01-2024
Pakkausseloste Pakkausseloste liettua 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto liettua 17-01-2024
Pakkausseloste Pakkausseloste unkari 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto unkari 17-01-2024
Pakkausseloste Pakkausseloste malta 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto malta 17-01-2024
Pakkausseloste Pakkausseloste hollanti 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto hollanti 17-01-2024
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta hollanti 16-05-2014
Pakkausseloste Pakkausseloste puola 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto puola 17-01-2024
Pakkausseloste Pakkausseloste portugali 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto portugali 17-01-2024
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta portugali 16-05-2014
Pakkausseloste Pakkausseloste romania 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto romania 17-01-2024
Pakkausseloste Pakkausseloste slovakki 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto slovakki 17-01-2024
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta slovakki 16-05-2014
Pakkausseloste Pakkausseloste sloveeni 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto sloveeni 17-01-2024
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta sloveeni 16-05-2014
Pakkausseloste Pakkausseloste suomi 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto suomi 17-01-2024
Pakkausseloste Pakkausseloste ruotsi 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto ruotsi 17-01-2024
Pakkausseloste Pakkausseloste norja 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto norja 17-01-2024
Pakkausseloste Pakkausseloste islanti 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto islanti 17-01-2024
Pakkausseloste Pakkausseloste kroatia 17-01-2024
Valmisteyhteenveto Valmisteyhteenveto kroatia 17-01-2024

Etsi tähän tuotteeseen liittyviä ilmoituksia

Näytä asiakirjojen historia